FDA Konakion

1

Click here to load reader

description

discontinued in US

Transcript of FDA Konakion

  • 6/12/2015 Drugs@FDA:FDAApprovedDrugProducts

    http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails 1/3

    FAQ6|Instructions7|Glossary8|ContactUs9

    EmailLink

    DrugDetails

    DrugName(s) KONAKIONFDAApplicationNo. (NDA)011745ActiveIngredient(s) PHYTONADIONECompany ROCHEChemicalType 5NewformulationornewmanufacturerReviewClassification SStandardreviewdrug

    TherearenoTherapeuticEquivalents Labelsarenotavailable

    ApprovalHistoryandRelatedDocumentsarenotavailable

    ProductsonApplication(NDA)#011745Clickonacolumnheadertoresortthetable:

    DrugName ActiveIngredients Strength DosageForm/Route MarketingStatus

    RLD TECode

    KONAKION PHYTONADIONE 1MG/0.5ML INJECTABLEINJECTION Discontinued No NoneKONAKION PHYTONADIONE 10MG/ML INJECTABLEINJECTION Discontinued No None

    BacktoTop|BacktoPreviousPage|BacktoDrugs@FDAHome

    Disclaimer10

    FDA Home3 Drug Databases4 Drugs@FDA5


Fda audit series part 3, while the fda is there

Fda audit series part 3, while the fda is there

FDA Inspections ( How to Survive an FDA Inspection).ppt

FDA Inspections ( How to Survive an FDA Inspection).ppt

FDA Hygiene

FDA Hygiene

Flavonoides fda

Flavonoides fda

FDA guidance, FDA compliance, FDA consulting, FDA regulations, …compliancegurus.com/files/pharmamay09.pdf · 2018. 11. 12. · Data integrity was seen in the Warning Letter sent

FDA guidance, FDA compliance, FDA consulting, FDA regulations, …compliancegurus.com/files/pharmamay09.pdf · 2018. 11. 12. · Data integrity was seen in the Warning Letter sent

FDA - maff.go.jp

FDA - maff.go.jp

Krystexxa FDA

Krystexxa FDA

Quality by Design Approaches to Analytical Methods -- FDA ... fda/published... · 1 Quality by Design Approaches to Analytical Methods -- FDA Perspective Yubing Tang, Ph.D. FDA/CDER/ONDQA.

Quality by Design Approaches to Analytical Methods -- FDA ... fda/published... · 1 Quality by Design Approaches to Analytical Methods -- FDA Perspective Yubing Tang, Ph.D. FDA/CDER/ONDQA.

Metformin FDA

Metformin FDA

Improving FDA/Industry Interactions: Suggestions from FDA/CDER Statisticians

Improving FDA/Industry Interactions: Suggestions from FDA/CDER Statisticians

THE EMERGENCY GUIDE TO FDA WARNING LETTERS & FDA 483 · 2018-12-13 · The Emergenc Gide to FDA Warning Letters & FDA 483 The FDAGrop.com 4 FDA 483 RESOLVING FDA 483 OBSERVATIONS

THE EMERGENCY GUIDE TO FDA WARNING LETTERS & FDA 483 · 2018-12-13 · The Emergenc Gide to FDA Warning Letters & FDA 483 The FDAGrop.com 4 FDA 483 RESOLVING FDA 483 OBSERVATIONS

Food & Beverage Industry Brochure - daemar.com · applications including: FDA Silcone, FDA EPDM, FDA NBR, FDA Neoprene, FDA FKM (Viton), FDA PTFE, FDA PTFE Encapsulated, FFKM (Kalrez).

Food & Beverage Industry Brochure - daemar.com · applications including: FDA Silcone, FDA EPDM, FDA NBR, FDA Neoprene, FDA FKM (Viton), FDA PTFE, FDA PTFE Encapsulated, FFKM (Kalrez).

FDA Pleconaril

FDA Pleconaril

Zaptivke FDA

Zaptivke FDA

FDA Guidance

FDA Guidance

FDA Overview

FDA Overview

FDA Assignment

FDA Assignment

FDA: Feature Disruptive Attack - openaccess.thecvf.comopenaccess.thecvf.com/content_ICCV_2019/papers/... · motivation, we introduce FDA: Feature Disruptive attack. FDA generates

FDA: Feature Disruptive Attack - openaccess.thecvf.comopenaccess.thecvf.com/content_ICCV_2019/papers/... · motivation, we introduce FDA: Feature Disruptive attack. FDA generates

FDA Oral History Interviews, FDA retired scientists

FDA Oral History Interviews, FDA retired scientists

FDA Updates

FDA Updates